Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pfizer's CDK4/6 inhibitor approved for advanced breast cancer

Nature Biotechnology volume 33, pages 323–324 (2015)Cite this article

Subjects

CDKs are enzymes implicated in cell replication, and their role in tumor growth has long made them into attractive drug targets. But early industry attempts at inhibiting CDKs to restore cell growth to normal have encountered toxicity issues. First-generation CDK inhibitors were nonspecific, inhibiting many different CDKs (there are more than 20, many of which have been implicated in various tumor types), and resulting in the type of toxicities and muted efficacy seen with older chemotherapies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Yardley, Pennsylvania

    Chris Morrison

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Pfizer's CDK4/6 inhibitor approved for advanced breast cancer. Nat Biotechnol 33, 323–324 (2015). https://doi.org/10.1038/nbt0415-323

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0415-323

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer